Concepedia

Robin J. Gunn

RJ

12

Publications

1.7K

Citations

12

H-Index

2014

Active since

Affiliations

Mirati Therapeutics (United States)(Current)

Scripps Research Institute

Emory University

Pfizer (United States)

Robin J. Gunn is an author at Mirati Therapeutics (United States) specializing in medicine, immunology, and molecular biology.

ORCID

Top concepts

Publications per year

2014–2024

12

Publications

12

Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor

Xiaolun Wang, Shelley Allen, James F. Blake et al. · Journal of Medicinal Chemistry · 2021 · 644 citations · Full text

Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor

Jill Hallin, Vickie Bowcut, Andrew Calinisan et al. · Nature Medicine · 2022 · 465 citations

, , +7

HMGB1 Activates Proinflammatory Signaling via TLR5 Leading to Allodynia

Nabanita Das, Varun Dewan, Peter M. Grace et al. · Cell Reports · 2016 · 150 citations · Full text

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers

Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski et al. · Journal of Medicinal Chemistry · 2022 · 139 citations · Full text

Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein–Protein Interaction

John M. Ketcham, Jacob R. Haling, Shilpi Khare et al. · Journal of Medicinal Chemistry · 2022 · 87 citations · Full text

Rows per page

1–5 of 12